Mankind Pharma Ltd Quarterly Results Q1FY27 stock analysis

Home » Core Investor Group » Mankind Pharma Ltd Q1FY27 Result Update

Sector Outlook: Neutral

Strong domestic execution and BSV momentum reinforce long-term growth visibility

The company reported revenue growth of 12.9% YoY / 17.1% QoQ to Rs. 40,306 mn, ahead of our expectations, driven by broad-based strength in the domestic formulations business, continued outperformance in chronic therapies, robust BSV specialty growth and strong international business performance. Domestic formulations (excluding consumer healthcare) grew 11.0% YoY, supported by healthy growth across cardiac, anti-diabetic, gastro, gynecology, vitamins, and respiratory therapies, while the acute portfolio continued its recovery, with growth broadly in line with the IPM. Chronic business remained a key growth driver, increasing 15.8% YoY, with chronic contribution improving to nearly 40% of domestic sales, reflecting the company’s continued strategic shift towards high-value therapies. International business registered a strong 29% YoY growth, aided by BSV exports, new product launches in the US and favorable currency movement. EBITDA increased 24.7% YoY / up 13.6% QoQ to Rs. 10,562 mn, while EBITDA margin stood at 26.2% (up 249bps QoQ) in Q1FY27, supported by better product mix, price increases and higher contribution from chronic therapies. PAT increased 29.1% YoY to Rs. 5,741 mn, with PAT margin improving to 14.2% versus 12.5% in the corresponding quarter last year. Management reiterated its FY27 guidance of double-digit revenue growth, EBITDA margin of 25.5% – 26.5%, continued chronic outperformance and sustained recovery in the acute portfolio.

Valuation and Outlook

Mankind Pharma delivered another strong quarter, supported by improving execution across its domestic formulations business, sustained momentum in chronic therapies, and accelerating growth from the BSV franchise. Recovery in the acute portfolio, improving prescription share, stronger volume growth and increasing contribution from cardiac, anti-diabetic, gastro and women’s healthcare therapies continue to strengthen the business mix. Gross margin expansion, operating leverage and lower finance costs resulted in healthy earnings growth, while disciplined execution continues to improve profitability. Looking ahead, management remains confident in sustaining double-digit domestic growth, supported by continued chronic expansion, improving hospital penetration, normalization in acute therapies, and higher contribution from specialty businesses. BSV is expected to maintain high-teen growth, driven by fertility, IVF and women’s healthcare products alongside expanding international presence. The company also continues to invest in biologics and specialty capabilities through its Vadodara biotech facility, increased R&D spending and strategic product launches. Despite near-term risks from elevated raw material costs and geopolitical uncertainties, strong brand equity, improving operating metrics, declining leverage, and an expanding specialty portfolio provide healthy long-term earnings visibility. Overall, we remain positive on Mankind Pharma given its strong domestic franchise, improving product mix and long-term growth opportunities across chronic, specialty and international businesses. Thus, we expect Mankind Pharma to generate stable revenues over the long term and is trading at a PE of 51.2x/39.4x on FY27e/28e EPS estimates. We value Mankind Pharma at 46x FY27e EPS and have revised the target price to Rs 2,889.

Key concall Highlights

Domestic Business Outlook:

Management highlighted that the domestic business has returned to a healthy double-digit growth trajectory, supported by recovery in the acute portfolio, sustained outperformance in chronic therapies and strong momentum in the BSV specialty business. The company expects to progressively outperform IPM over the medium term, driven by increasing chronic contribution, expansion in hospital business, launch of the new Vistar division for under-promoted brands and deeper penetration in under-served states.

Acute profile:

Acute therapies continued to recover during Q1FY27 with growth improving to 10.9%, broadly in line with industry growth. Gastro, vitamins, gynecology, ophthalmology and anti-infective therapies witnessed sequential improvement supported by better field execution, lower attrition, improving prescription trends and stronger doctor engagement. Management expects further gradual recovery through FY27.

India Consumer Healthcare Business:

The Consumer Healthcare business reported relatively muted growth during the quarter due to the rationalization of the cash-and-carry channel, although market share improved across key brands including Manforce, Prega News and Gas-O-Fast. Modern trade and e-commerce contribution increased to 15% from 11% in the corresponding period last year, supported by strong channel growth. Management expects the business to return to high-single-digit to double-digit growth from Q2FY27 onwards.

International Business Outlook:

International business recorded strong 29% YoY growth during the quarter driven by BSV exports, new US launches and favorable currency movement. Management continues to guide for high-teen constant currency growth, supported by new product launches, deeper penetration across existing markets and continued expansion of specialty and women’s healthcare products.

R&D Pipeline:

The company continues to strengthen its innovation pipeline with increasing investments in specialty products, biologics and differentiated therapies. R&D spending stood at 2.4% of sales during the quarter and is expected to increase to 2.8%-3.0% for FY27. Additionally, the strategic collaboration with Denovo Sciences for AI-led drug discovery is expected to enhance the company’s long-term innovation and product development capabilities.

BSV Portfolio:

BSV continued to deliver strong performance with around 21% growth during the quarter. Domestic BSV grew approximately 17%, while international business expanded around 25%. Growth was led by fertility, IVF and women’s healthcare products including Foligraf, Anti-D and other specialty brands, supported by wider gynecologist coverage, expanding IVF programs, increasing scientific engagement and new international approvals.

Capex:

Capex during Q1FY27 stood at Rs. 198 crores (4.9% of sales). Management reiterated its FY27 Capex guidance of 6% – 7% of revenue, primarily towards manufacturing expansion, R&D infrastructure and specialty capabilities. The company also remains on track to fully repay acquisition related debt by FY28, reflecting continued balance sheet strengthening.